Catalyst Pharmaceuticals, Inc. reported a total revenue of approximately $149.4 million for the first quarter of 2026, reflecting a 5.6% increase from $141.4 million in the same period of 2025. The growth was primarily driven by a notable rise in sales of FIRDAPSE® and AGAMREE®, which saw increases of 18.1% and 66.6%, respectively. However, revenue from FYCOMPA® decreased significantly by 61.3% due to the entry of generic competitors following the expiration of its patent. The company’s net income for the quarter was approximately $63.7 million, or $0.52 per share, compared to $56.7 million, or $0.47 per share, in the prior year.

In terms of operational metrics, Catalyst's cash and cash equivalents increased to $755.9 million as of March 31, 2026, up from $709.2 million at the end of 2025. The company also reported a decrease in total current liabilities from $147.2 million to $132.4 million, indicating improved financial health. The total stockholders' equity rose to $1.01 billion, up from $954.3 million, reflecting the company's profitability and effective management of its resources.

Strategically, Catalyst has made significant moves to expand its product portfolio. In 2023, the company acquired the U.S. rights to FYCOMPA® from Eisai and entered into a license agreement for AGAMREE® with Santhera Pharmaceuticals. The FDA approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in October 2023, and the product was commercially launched in the U.S. in March 2024. Additionally, Catalyst announced a merger agreement with Angelini Pharma in May 2026, which will see the company become a wholly-owned subsidiary of Angelini Pharma, with shareholders receiving $31.50 per share in cash.

Looking ahead, Catalyst anticipates continued growth in revenues from FIRDAPSE® and AGAMREE®, while acknowledging the challenges posed by generic competition for FYCOMPA®. The company plans to leverage its strong cash position to support ongoing operations and potential acquisitions. Catalyst's management expressed confidence in its ability to navigate the evolving pharmaceutical landscape, although they noted that future performance may be influenced by various factors, including market conditions and regulatory developments.

About CATALYST PHARMACEUTICALS, INC.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company specializing in in-licensing, developing, and commercializing treatments for rare and difficult-to-treat diseases. Its core products include FIRDAPSE® for Lambert-Eaton myasthenic syndrome, FYCOMPA® for epilepsy, and AGAMREE® for Duchenne muscular dystrophy. Catalyst targets niche patient populations through specialized sales forces, personalized patient support programs, and partnerships, focusing on orphan drug markets with strong intellectual property protections.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.